Lilly acquires new injectable medicine manufacturing facility from Nexus Pharmaceuticals
Upon completion, this acquisition will expand Lilly's growing U.S. capacity to produce the latest life-changing medicines
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Apr 24
Upon completion, this acquisition will expand Lilly's growing U.S. capacity to produce the latest life-changing medicines
26 Mar 24
Cardior is engaged in the discovery and development of therapies that prevent, repair and reverse diseases of the…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Mar 24
The deal is anticipated to boost Lonza's large-scale biologics manufacturing capacity and will also help the firm cope…
19 Mar 24
The transaction complements AstraZeneca’s oncology portfolio with Fusion’s pipeline of RCs, including its lead programme FPI-2265, and replaces…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
15 Mar 24
AstraZeneca said that the acquisition will further expand the pipeline of Alexion, AstraZeneca Rare Disease, beyond complement inhibition,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Mar 24
Acoramidis is an investigational, next-generation, orally administered, highly potent and selective small molecule transthyretin (TTR) stabiliser, intended for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Feb 24
Ginkgo Bioworks has acquired synthetic biology company Patch Biosciences, pharmaceutical company Reverie Labs, and CRISPR-based diagnostic test developer…
15 Feb 24
Brii Biosciences also agreed to acquire manufacturing capabilities and certain related assets and will also remove payment obligations…
13 Feb 24
Through the acquisition, Gilead will add Seladelpar, an investigational, oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist intended…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Feb 24
Novo Nordisk has agreed to acquire Catalent’s three fill-finish sites located in Anagni, Italy; Brussels, Belgium; and Bloomington,…